Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ

Bioorganic & Medicinal Chemistry Letters
Alexandria A OviattNeil Osheroff

Abstract

Etoposide is an anticancer drug that acts by inducing topoisomerase II-mediated DNA cleavage. Despite its wide use, etoposide is associated with some very serious side-effects including the development of treatment-related acute myelogenous leukemias. Etoposide targets both human topoisomerase IIα and IIβ. However, the contributions of the two enzyme isoforms to the therapeutic vs. leukemogenic properties of the drug are unclear. In order to develop an etoposide-based drug with specificity for cancer cells that express an active polyamine transport system, the sugar moiety of the drug has been replaced with a polyamine tail. To analyze the effects of this substitution on the specificity of hybrid molecules toward the two enzyme isoforms, we analyzed the activity of a series of etoposide-polyamine hybrids toward human topoisomerase IIα and IIβ. All of the compounds displayed an ability to induce enzyme-mediated DNA cleavage that was comparable to or higher than that of etoposide. Relative to the parent drug, the hybrid compounds displayed substantially higher activity toward topoisomerase IIβ than IIα. Modeling studies suggest that the enhanced specificity may result from interactions with Gln778 in topoisomerase IIβ. The corres...Continue Reading

References

Dec 11, 2002·The Journal of Biological Chemistry·Kenneth D BrombergNeil Osheroff
Aug 17, 2005·Current Medicinal Chemistry. Anti-cancer Agents·E L Baldwin, N Osheroff
Jul 22, 2006·DNA Repair·Carolyn A FelixNeil Osheroff
Jun 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anna M AzarovaLeroy F Liu
Dec 2, 2008·Nucleic Acids Research·Joseph E Deweese, Neil Osheroff
Feb 20, 2009·Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology·Joseph E DeweeseNeil Osheroff
Apr 21, 2009·Nature Reviews. Cancer·John L Nitiss
Apr 21, 2009·Nature Reviews. Cancer·John L Nitiss
Sep 25, 2009·Investigational New Drugs·Anna KruczynskiNicolas Guilbaud
Nov 24, 2011·Nature Reviews. Molecular Cell Biology·Seychelle M VosJames M Berger
Nov 24, 2011·Mediterranean Journal of Hematology and Infectious Diseases·M JoannidesD Grimwade
May 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ian G CowellCaroline A Austin
Jul 26, 2012·International Journal of Environmental Research and Public Health·Ian G Cowell, Caroline A Austin
Dec 25, 2012·ACS Chemical Biology·Yves Pommier
Mar 19, 2013·Annual Review of Biochemistry·Stefanie Hartman ChenTao-shih Hsieh
Jul 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dominique TiernyBruno Gomes
Oct 21, 2016·Nature Reviews. Molecular Cell Biology·Yves PommierJohn L Nitiss
Oct 28, 2017·Journal of Medicinal Chemistry·Jose Antonio OrtegaMarco De Vivo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.